(Q36636656)

15 August 2017

1 reference

title

Chemotherapy practices and perspectives in invasive bladder cancer (English)

1 reference

15 August 2017

Aude Flechon

1

1 reference

PubMed ID

17069531

15 August 2017

Jean-Pierre Droz

series ordinal

2

1 reference

PubMed ID

17069531

15 August 2017

language of work or name

1 reference

1 October 2006

1 reference

Expert Review of Anticancer Therapy

15 August 2017

1 reference

15 August 2017

6

1 reference

15 August 2017

1473-1482

1 reference

15 August 2017

10

1 reference

Molecular biology of transitional cell carcinoma

15 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Profiles of the 2 INK4a gene products, p16 and p14ARF, in human reference urothelium and bladder carcinomas, according to pRb and p53 protein status.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Management of muscle-invasive bladder cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Management and geriatric assessment of cancer in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Overview of bladder cancer trials in the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Methotrexate: an active drug in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Adriamycin in advanced urinary tract cancer.Experience in 42 patients and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Gemcitabine in locally advanced and/or metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Accumulation of nuclear p53 and tumor progression in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Screening for renal disease using serum creatinine: who are we missing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Single-agent gemcitabine in previously untreated elderly patients with advanced bladder carcinoma: response to treatment and correlation with the comprehensive geriatric assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Expression of Frzb/secreted Frizzled-related protein 3, a secreted Wnt antagonist, in human androgen-independent prostate cancer PC-3 cells suppresses tumor growth and cellular invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.6.10.1473

Flavokawain A, a novel chalcone from kava extract, induces apoptosis in bladder cancer cells by involvement of Bax protein-dependent and mitochondria-dependent apoptotic pathway and suppresses tumor growth in mice

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.1158/0008-5472.CAN-04-3803

Identifiers

DOI

10.1586/14737140.6.10.1473

1 reference

15 August 2017

1 reference

PubMed ID

17069531